Zhong Nanshan: The epidemic may continue to exist this winter and next spring, or the development of 4 vaccines will enter Phase III clinical trials
China News Service, Beijing, September 18 (Reporter Yu Lixiao) The epidemic may continue to exist or develop this winter and next spring. After the epidemic is found in some areas, joint prevention and control at the community level, community-wide nucleic acid screening, tracking of close contacts, and isolation Nucleic acid-positive asymptomatic patients and other methods are effective.
Zhong Nanshan, head of the expert group of the State Council's Joint Prevention and Control Mechanism Scientific Research Team and Director of the National Respiratory Disease Clinical Medicine Research Center, made the above statement at the Global Science, Life and Health Forum held on the 18th.
The Global Science and Life and Health Forum is one of the parallel forums of the 2020 Zhongguancun Forum. Scientists from all over the world share their experience in anti-epidemic and scientific research and discuss topics such as vaccine development, drug screening and clinical treatment, etiology and transmission routes, and testing reagents.
According to Zhong Nanshan, it takes time for mass vaccination to form a herd immune barrier.
China Vaccine has completed Phase I and Phase II clinical trials, and 4 vaccines have entered the Phase III clinical trials.
Zhong Nanshan said that China has cooperated with more than 40 countries in the world for the new crown pneumonia vaccine, and has been approved to conduct Phase III clinical trials in Brazil, Indonesia, the United Arab Emirates, Russia, Peru, Argentina, Morocco and other countries. Four vaccines have entered into international cooperation. Phase III clinical trial stage.
According to Chen Wei of the Military Medical College of the Academy of Military Sciences, the virus mutation has no obvious effect on the vaccine.
At present, the safety of six recombinant new crown vaccines that have published clinical data around the world has been compared. These vaccines are from China, Russia, the United Kingdom, the United States and Germany.
China’s Minister of Science and Technology Wang Zhigang revealed that China has 11 new coronary pneumonia vaccines in clinical trials, 4 of which have entered phase III clinical trials.
According to Wang Zhigang, since the outbreak of the epidemic, Chinese scientific and technological circles and scientific researchers have devoted themselves to scientific research on epidemic prevention and control, focusing on five key directions including drug screening, vaccine research and development, detection technology, viral etiology and epidemiology, and animal models. A batch of effective treatment drugs and treatment methods have been evaluated to form treatment methods suitable for patients at different stages.
At the same time, Chinese scientific and technical personnel completed the research and development of nucleic acid detection, antibody detection reagents and supporting equipment in a short period of time to meet the detection needs of different application scenarios, and promote inactivated vaccines, adenovirus vector vaccines, recombinant protein vaccines, nucleic acid vaccines, and attenuation in parallel. Research and development of 5 technical routes including influenza vaccine.
Wang Zhigang said that the current new crown pneumonia epidemic is still spreading globally and has not been fully controlled. With the arrival of this autumn and winter, the epidemic may rebound, and the prevention and control situation is still severe. (Finish)